Imugene Ltd IMU
ASX · Australia · Health Technology
AUD 0.0390-0.00 (-7.14%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is raising about A$11.12 million before costs through a two-tranche placement, strengthening its balance sheet as it advances its lead cell therapy asset azer-cel through key clinical and regulatory milestones. The placement follows positive early...
Imugene Ltd (ASX:IMU, OTC:IUGNF) earlier this week reported a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial, adding momentum to an early clinical signal in patients with limited remaining treatment...
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial, marking an early clinical signal in a patient population with limited remaining treatment...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.